P Pu ur rp po os se e: : Congenital long QT syndrome is characterized by a corrected QT interval of at least 440 msec on the electrocardiogram and has been associated with recurrent syncope, documented ventricular arrhythmia and sudden death. There have been numerous articles over the past 20 years describing isolated instances of surgical and anesthesia related complications but the general anesthetic management of the condition remains unclear.
Objectif : Le syndrome congénital du QT long est caractérisé par un intervalle QT corrigé d'au moins 440 msec à l'électrocardiogramme et est associé à des syncopes récurrentes, de l'arythmie ventriculaire reconnue et la mort subite. Au cours des 20 dernières années, de nombreux articles ont présenté des cas isolés de complications reliées à la chirurgie et à l'anesthésie, mais la prise en charge anesthésique est encore indéterminée dans ces conditions.
Éléments cliniques : Une fillette de ONGENITAL long QT syndrome (LGTS) can be inherited either in association with congenital deafness (Jervell and Lange-Nielson syndrome), 1 or with no other associated physical anomalies (Romano-Ward syndrome). 2 During the past decade, at least six different genetic defects, all involving potassium or sodium transmission, have been discovered to lead to one form or another of LQTS. 3 The most common, LQT 1, is a defect on chromosome 11, encoding for the potassium channel. The next most common, LQT 2, is a defect on chromosome 7, again encoding for the potassium channel. It is thought that LQT 1 and 2 together represent approximately 95% of all cases. LQT 3 (3-4% of cases) is a defect on chromosome 3, encoding for the sodium channel. LQT 4, 5 and 6 all involve defects in potassium transmission, are located on chromosomes 4, 21 and 21, respectively, and are quite rare. All the genetic subtypes are characterized by a corrected QT interval of at least 440 msec on the 4 There have been numerous articles over the past 20 years describing isolated instances of surgical and anesthesia related complications but the general anesthetic management of the condition remains unclear. We present the case of an 11-yr-old child presenting for emergency surgery requiring general anesthesia, who suffered ventricular tachycardia during surgery. We also present a review of the literature and recommendations for dealing with such cases in the future.
C Ca as se e r re ep po or rt t An 11-yr-old female was admitted to the pediatric service with a four-day history of left eye swelling and pain, accompanied by fever. Her past medical history was significant for documented LQTS, with two episodes of syncope in the past. Her mother and two siblings had also been diagnosed with LQTS (Romano-Ward). The patient had begun taking atenolol approximately two years prior to the current admission. A few months after beginning therapy with atenolol, she suffered an episode of syncope, and the dose was then increased.
She was brought to the operating room for left ethmoidectomy and drainage of periorbital abscess. The patient's preoperative ECG ( Figure 1 ) revealed prolonged QT interval with no arrhythmia.
The patient weighed 46 kg. She received midazolam 1 mg intravenously prior to anesthetic induction. She was given oxygen 100% by mask and anesthesia was induced with fentanyl 200 µg and propofol 80 mg, with rocuronium 20 mg for muscle relaxation. Tracheal intubation was easily accomplished and anesthesia initially maintained with nitrous oxide, fentanyl and oxygen. Vital signs remained stable, with heart rate (HR) at 82 beats·min -1 . She was given iv labetalol 5 mg and HR decreased to approximately 60 beats·min -1 . Prior to the start of surgery, halothane 0.8% was initiated. Vital signs remained stable until approximately 20 min into the case, when the patient developed, first bigeminy, then ventricular tachycardia (torsade de pointes) at a rate of 130 beats·min -1 . Blood pressure decreased to a mean of 45 mmHg. Lidocaine 40 mg was given intravenously on the advice of cardiology. Halothane and nitrous oxide were discontinued and isoflurane 1% substituted. Cardiac rhythm returned to normal sinus and there were no further arrhythmias throughout the case. Muscle relaxation was reversed with neostigmine 2.0 mg and glycopyrrolate 0.4 mg and the trachea extubated. ETCO 2 remained between 32 and 34 mmHg and oxygen saturation was 99-100% for the entire case. No further adverse events occurred. End-tidal halothane concentration was measured but not recorded, and until discontinued, was thought to be appropriate to the vaporizer settings. The patient was transferred to the pediatric intensive care unit in stable condition.
A few months after discharge, the patient's younger brother suddenly died, presumably secondary to an episode of ventricular tachycardia. Her older brother then had an automatic implantable cardioverter defibrillator (AICD) placed but the patient was at that time unwilling to accept such a procedure for herself. Her dosage of atenolol was again increased but the patient suffered an episode of syncope approximately one year after the drainage of her periorbital abscess. She was admitted to a neighbouring hospital where an esmolol infusion was started. While in the hospital, she suffered an episode of ventricular tachycardia and was transferred to our institution. The esmolol was continued, the atenolol dosage again increased and a lidocaine infusion started. The patient again suffered an episode of ventricular tachycardia (Figure 2 ) and the decision was made to place an AICD. For this procedure, she received midazolam 2 mg, diphenhydramine 25 mg, fentanyl 100 µg, and propofol by infusion. She suffered no untoward incident during the procedure. Subsequent to these events, genetic testing revealed a defect on chromosome 7, leading to a diagnosis of LQTS type 2 (LQT 2). D Di is sc cu us ss si io on n Idiopathic LQTS is characterized by episodes of syncope, more commonly in females, and has been associated with sudden death, particularly in the pediatric population. 4 Increased levels of catecholamines have been associated with arrhythmias, and LQTS is thought to be one of many possible etiologies of sudden infant death syndrome. 5 Once diagnosed, the standard treatment for LQT 1 and 2 is beta-adrenergic blockade, which has been shown to significantly reduce morbidity. 6 Beta-blockade may, however, be contra-indicated in LQT 3, since bradycardia in these patients can further prolong the QT interval and lead to ventricular arrhythmias. 7 In 1991, Moss et al., showed that cardiac pacing at a rate sufficient to shorten the QT interval could prove useful. 8 However, at the time this study was done, the various genetic sub-types of LQTS had not yet been identified, and recent data suggests that increasing the HR would probably be beneficial only in LQT 3. 7 Refractory acute arrhythmic episodes in association with LQTS may be treated by resection of the left stellate ganglion. 9 Intravenous magnesium has been used to break refractory arrhythmias 10 and treatment with an AICD has recently become a viable therapeutic option. 11 Procainamide and lidocaine have been thought to be contraindicated, due to their propensity to prolong the QT interval. 12 Nevertheless, lidocaine has been reported to successfully treat ventricular arrhythmias in LQTS. 13 The anesthetic management of these patients is controversial. The condition is rare, and there are no controlled clinical trials pointing to the advisability of one technique over another. Our patient arrived in the operating room at night and without prior warning. A MEDLINE search back to 1995 through the hospital Internet connection revealed no articles specifically dealing with the anesthetic management of her condition. However, we discovered an article by Michaloudis et al., examining the effect of both isoflurane and halothane on the QT interval in normal, healthy patients, which concluded that halothane would most likely be superior for patients with prolonged QT syndrome, since halothane shortened the QT interval more than did isoflurane.
14 A review of other sources available to us in the operating room revealed contradictory recommendations. Reich, Brooks and Kaplan recommend the use of high dose narcotics without nitrous oxide. 15 Stoelting, Dierdorf and McCammon give the opinion that nitrous oxide plus isoflurane or enflurane are acceptable, but state that "halothane is a less attractive alternative," due to the tendency of halothane to predispose to arrhythmias in the presence of catecholamines. 16 A postoperative search of the literature going back to 1977 revealed a number of reports that perhaps shed light on the question (Table) . Including our own, ten cases have been reported of patients receiving halothane. [17] [18] [19] [20] [21] [22] [23] Of these, four underwent surgery without incident; 17, 18 all four were taking medication and asymptomatic prior to surgery. In six cases, [19] [20] [21] [22] [23] patients who were either not under treatment or whose symptoms were not well controlled by treatment, suffered arrhythmias during surgery.
Eight patients received isoflurane, 21,24-27 six of whom suffered no untoward incident. Five of these six had been considered asymptomatic on medication.
Two patients received enflurane. One, whose symptoms were well controlled prior to surgery, suffered no untoward incident during two anesthetics. 28 One patient was symptomatic prior to surgery and had ventricular tachycardia during surgery. 29 Two patients received sevoflurane. Both were symptomatic prior to surgery. One had premature ventricular contractions (PVCs) 30 and the other suffered ventricular fibrillation during surgery. 31 Four patients had a nitrous oxide/narcotic anesthetic. All four were taking medication and asymptomatic prior to surgery. 18, 32 Three suffered no untoward incident. One had PVCs. 32 Three patients suffered arrhythmias during anesthetic induction. [33] [34] [35] All were symptomatic prior to surgery, though one had reportedly 34 earlier successful surgeries, and again had surgery after treatment, without untoward incident. In none of these three anesthetics was the specific anesthetic technique described.
One patient received ketamine twice, 19 on both occasions suffering significant arrhythmias. She was diagnosed with LQTS after the first incident and propranolol was begun. Nevertheless, she again suffered a life-threatening arrhythmia during surgery, after having received 10 mg·kg -1 oral ketamine. An article by Galloway and Glass, published in 1985, gives the opinion that isoflurane is most likely a safer anesthetic than halothane. 36 Though this opinion may be true, a review of the literature does not necessarily support such a conclusion. On the other hand, our review of the literature suggests that patients whose symptoms are not well controlled prior to surgery are likely to suffer arrhythmias during surgery, regardless of the anesthetic technique chosen.
Unfortunately, genetic testing is still not readily available, and it may not be possible to determine with certainty a particular patient's genotype. However, at least one recent article claims that LQT 1, 2, and 3 can frequently be identified by the ECG pattern. 37 LQT 1 has a prolonged QT interval with a normal to high T wave amplitude, a broad based T wave, and an indistinct T wave onset. LQT 2 is characterized by a prolonged QT interval, low amplitude T waves, and bifid T waves in over 60% of cases. LQT 3 shows a prolonged QT interval with late onset, peaked T waves and a long, isoelectric ST segment. Of note, our patient does have the bifid T wave pattern supposedly characteristic of LQT 2 ( Figure 1 ).
Since LQT 1 and 2 are the most common forms, preoperative beta-adrenergic blockade would certainly seem advisable if a diagnosis of LQTS has been confirmed but the specific genetic abnormality has not yet been identified. If known to be LQT 3, however, beta-blockade should probably be avoided, and during surgery, rapid cardiac pacing should be available in the operating room. It would perhaps be prudent to avoid both halothane and ketamine, and also, as far as possible, situations involving stress and subsequent catecholamine release. If a patient's symptoms can be controlled prior to surgery -by whatever means -it would seem advisable to do so. Numerous drugs prolong the QT interval, and should be avoided. An excellent listing of such drugs is contained on the website http://www.torsades.org/druglist.cfm, but among those most likely to be encountered in the operating room are amiodarone (Cordarone®), bepredil (Vascor®), cisapride (Propulsid®), chlorpromazine (Thorazine®), disopyramide (Norpace®), dolasetron (Anzemet®), droperidol (Inapsine®), erythromycin, flecainide (Tambocor®), fluoxetine (Prozac®), fosphenytoin (Cerebryx®), gatifloxacin (Tequin®), haloperidol (Haldol®), levofloxacin (Lecaquin®), nicardipine (Cardene®), paroxetine (Paxil®), procainamide (Pronestyl®, Procan®), risperidone (Risperdal®), salmeterol (Serevent®), sertraline (Zoloft®), sotalol (Betapace®), sumatriptan (Imitrex®), tamoxifen (Novadex®) and thioridazine (Mellaril®). QT interval should be monitored during surgery and the patient's cardiac rhythm should be monitored for a prolonged period after surgery. If arrhythmias occur -most typically torsade de pointesiv lidocaine or iv magnesium may prove effective, as may rapid cardiac pacing in LQT 3. If these fail, electrical defibrillation may be necessary. 
